Literature DB >> 18225587

The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel.

Akiko Kuwajima1, Jun Iwashita, Jun Murata, Tatsuya Abe.   

Abstract

BACKGROUND: Histone deacetylase (HDAC) inhibitors have anticancer effects. Their effects on expression of cell adhesion molecules might be related to their effects on tumor cell invasion.
MATERIALS AND METHODS: Murine B16-BL6 cells were treated with the HDAC inhibitors, butyrate or trichostatin A. Melanoma cell invasion of the artificial basement membrane, Matrigel, was examined by Transwell chamber assay.
RESULTS: Butyrate as well as trichostatin A inhibited the cell growth mainly by arresting the cell cycle. The cell invasion of Matrigel was inhibited by butyrate and trichostatin A. The butyrate treatment increased the cell-cell aggregation, although neither E-cadherin nor N-cadherin mRNA were up-regulated. Both mRNA expression and protein levels of the immunoglobulin superfamily cell adhesion molecules, Mel-CAM and L1-CAM, were increased in the butyrate-treated cells.
CONCLUSION: The HDAC inhibitor butyrate blocked the B16-BL6 melanoma cell invasion of Matrigel, although it increased the expression of Mel-CAM and L1-CAM which are important to the metastatic potential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18225587

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Downregulation of matrix metalloproteinases contributes to the inhibition of cell migration and invasion in HepG2 cells by sodium valproate.

Authors:  Xia Zhao; Weihua Yang; Fengyan Pei; Wanshan Ma; Yunshan Wang
Journal:  Oncol Lett       Date:  2015-05-13       Impact factor: 2.967

2.  Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.

Authors:  Veronika V Borutinskaite; Karl-Eric Magnusson; Ruta Navakauskiene
Journal:  Mol Biol Rep       Date:  2012-09-26       Impact factor: 2.316

Review 3.  Current trends in the development and application of molecular technologies for cancer epigenetics.

Authors:  Hyeran Jang; Hyunjin Shin
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

Review 4.  Targeting BRAF for patients with melanoma.

Authors:  H-T Arkenau; R Kefford; G V Long
Journal:  Br J Cancer       Date:  2010-12-07       Impact factor: 7.640

5.  L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions.

Authors:  Marco Pfeifer; Uwe Schirmer; Claudia Geismann; Heiner Schäfer; Susanne Sebens; Peter Altevogt
Journal:  BMC Mol Biol       Date:  2010-08-27       Impact factor: 2.946

Review 6.  HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases.

Authors:  Somy Yoon; Gwang Hyeon Eom
Journal:  Chonnam Med J       Date:  2016-01-19

7.  Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.

Authors:  Uwe Schirmer; Heidi Fiegl; Marco Pfeifer; Alain G Zeimet; Elisabeth Müller-Holzner; Peter K Bode; Verena Tischler; Peter Altevogt
Journal:  BMC Cancer       Date:  2013-03-26       Impact factor: 4.430

8.  Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.

Authors:  Uwe Schirmer; Kai Doberstein; Anne-Kathleen Rupp; Niko P Bretz; Daniela Wuttig; Helena Kiefel; Christian Breunig; Heidi Fiegl; Elisabeth Müller-Holzner; Robert Zeillinger; Eva Schuster; Alain G Zeimet; Holger Sültmann; Peter Altevogt
Journal:  Oncotarget       Date:  2014-01-30

9.  Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.

Authors:  María Díaz-Núñez; Alejandro Díez-Torre; Olivier De Wever; Ricardo Andrade; Jon Arluzea; Margarita Silió; Juan Aréchaga
Journal:  BMC Cancer       Date:  2016-08-22       Impact factor: 4.430

10.  Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.

Authors:  Jiaqi Liu; Jianying Gu; Zihao Feng; Yanhong Yang; Ningwen Zhu; Weiyue Lu; Fazhi Qi
Journal:  J Transl Med       Date:  2016-01-08       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.